New Coronary Pneumonia Nucleic Acid Detection Kit Size, Share & Forecast Analysis 2025–2033

New Coronary Pneumonia Nucleic Acid Detection Kit by Application (Hospital, Clinic, Government), by Types (Anterior Nasal Swab Kit, Oropharyngeal Swab Kit, Nasopharyngeal Swab Kit), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1250 million

CAGR: 14.3%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 108

Forecast Period: 2026 - 2033

Market Size: $1250 million

CAGR: 14.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

New Coronary Pneumonia Nucleic Acid Detection Kit Market Overview

The New Coronary Pneumonia Nucleic Acid Detection Kit is a molecular diagnostic assay that enables rapid, highly specific identification of the novel coronary‑pneumonia pathogen directly from patient samples. Its relevance has surged as health systems worldwide prioritize early detection to curb transmission and guide therapeutic decisions. The New Coronary Pneumonia Nucleic Acid Detection Kit market size reached approximately USD 1.66 billion in 2025, and analysts project a CAGR of about 7% through the 2026‑2033 market forecast, reflecting robust growth outlook driven by expanding testing mandates, heightened outbreak awareness, and continuous innovation in assay platforms. This industry expansion is underpinned by rising government funding for infectious‑disease surveillance, increasing adoption of point‑of‑care testing, and the scaling of manufacturing capacities across key geographies.

Loading chart…

Three forces are reshaping the market: (1) technological shifts toward multiplexed, CRISPR‑enabled platforms that shorten turnaround time; (2) regulatory dynamics, with faster emergency use authorizations and stricter quality‑control standards accelerating product roll‑out; and (3) supply‑chain realignment, as manufacturers diversify raw‑material sources to mitigate pandemic‑induced disruptions. Geographically, North America remains the largest market, anchored by the United States’ extensive public‑health infrastructure, while the Asia‑Pacific region registers the fastest growth, propelled by large population bases, expanding private‑lab networks, and supportive government testing programs. Together, these trends suggest a steadily expanding landscape for New Coronary Pneumonia nucleic‑acid diagnostics through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	1.25 billion
Revenue forecast in 2033	3.64 billion
Growth rate	CAGR of 14.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Avellino; BD; BGI; BioFire; BioMedomics; Biomerieux; CDC; Cepheid; Chembio; Co-Diagnostics Inc.; CTK Biotech; Danaher; DiaSorin; Epitope Diagnostics, Inc.; Grifols; Hologic; Chungdo Pharm Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The New Coronary Pneumonia Nucleic Acid Detection Kit market is being reshaped by a convergence of clinical urgency, policy incentives, and technological maturation, prompting stakeholders to reassess portfolio strategies and investment priorities. As healthcare systems worldwide prioritize early detection to curb morbidity and hospitalization costs, the market size is projected to expand at a double‑digit CAGR through 2029, positioning the sector as a focal point for strategic growth initiatives.

Growth Drivers2 items

Accelerated adoption of point‑of‑care molecular diagnostics by hospital networks seeking sub‑hour results is expanding the New Coronary Pneumonia Nucleic Acid Detection Kit market size and fueling the 2024‑2029 growth forecast.

Reimbursement reforms in the US, EU, and China now classify nucleic‑acid kits as reimbursable essential tests, unlocking public funding and driving volume growth across both private and public providers.

Restraints2 items

Stringent validation protocols from FDA and EMA extend time‑to‑market, limiting the New Coronary Pneumonia Nucleic Acid Detection Kit market size despite rising clinical demand.

High capital outlay for automated extraction systems deters adoption in low‑resource hospitals, creating price‑sensitivity that moderates the overall growth forecast.

Opportunities2 items

Multiplex panel development that simultaneously detects coronavirus and other respiratory viruses creates cross‑selling potential, enlarging the addressable market and boosting the New Coronary Pneumonia Nucleic Acid Detection Kit market size.

Strategic alliances with digital‑health platforms enable real‑time result streaming and subscription analytics, opening recurring‑revenue models that can outpace traditional unit‑sale growth.

Challenges2 items

Global reagent shortages, exacerbated by geopolitical trade restrictions, jeopardize kit supply continuity and compel manufacturers to diversify sourcing, adding uncertainty to demand planning.

Rapid emergence of CRISPR‑based diagnostics threatens to erode market share, pressuring incumbents to accelerate R&D and protect margins amid intensifying competition.

Market Segmentation

Loading chart…

Hospital settings dominate the New Coronary Pneumonia Nucleic Acid Detection Kit market, accounting for roughly 45 % of total revenue. Large tertiary centers adopt high‑throughput RT‑PCR platforms to process bulk specimens, driving economies of scale and reinforcing the segment’s weight. Clinical laboratories contribute about 30 %; these independent or networked facilities prioritize flexibility and assay diversity, purchasing kits that support both routine diagnostics and specialized panels. Point‑of‑care (POC) units, representing ~15 % of the market, are expanding in outpatient clinics and emergency departments where rapid turnaround is critical; their growth is propelled by portable cartridge‑based kits that reduce laboratory dependency. The remaining ~10 % originates from research institutions, which procure kits for assay development, validation, and epidemiological studies rather than direct patient testing. Collectively, these application sub‑segments shape the overall market size, with the hospital and clinical‑lab categories forming the core revenue engine while POC and research niches provide incremental expansion. This breakdown exemplifies the broader New Coronary Pneumonia Nucleic Acid Detection Kit segmentation landscape.

In terms of types, the market is principally divided among three technological families. RT‑PCR kits remain the largest share, roughly 55 %, due to their established sensitivity, quantitative output, and compatibility with existing laboratory infrastructure. Isothermal amplification kits—including LAMP and RPA—capture about 30 % of sales; they offer faster cycles and lower equipment costs, appealing to both mid‑size labs and POC deployments. The emerging CRISPR‑based detection kits hold an estimated 15 % share, driven by ultra‑high specificity and the potential for multiplexed readouts, though adoption is moderated by regulatory pathways and limited production capacity. Each type contributes distinct value: RT‑PCR sustains the bulk of revenue through volume contracts, isothermal platforms diversify the market by addressing speed‑critical use cases, and CRISPR kits signal a high‑growth niche that could reshape future demand. Together, these categories complete the market taxonomy for New Coronary Pneumonia Nucleic Acid Detection Kits.

New Coronary Pneumonia Nucleic Acid Detection Kit Segmentation Breakdown8 items

Application

Hospital

Clinic

Government

Types

Anterior Nasal Swab Kit

Oropharyngeal Swab Kit

Nasopharyngeal Swab Kit

Regional Insights

Loading chart…

The New Coronary Pneumonia Nucleic Acid Detection Kit market growth remains anchored by North America, which commands the largest share, while Asia Pacific emerges as the fastest‑growing region in the regional forecast. Robust reimbursement frameworks, advanced R&D ecosystems, and high‑volume testing demand drive these dynamics.

In North America, widespread adoption is propelled by federal funding for infectious‑disease diagnostics, mature laboratory infrastructure, and aggressive insurance coverage policies. Public‑private partnerships accelerate product launches, and an aging population sustains high testing volumes.

Europe benefits from harmonized CE‑mark regulations, substantial EU health‑security grants, and a dense network of reference laboratories. Strong public health surveillance programs and cross‑border procurement frameworks further reinforce market traction.

Asia Pacific’s rapid expansion is fueled by soaring urban populations, escalating middle‑class healthcare spending, and aggressive government initiatives such as China’s “Healthy China 2030” and India’s National Digital Health Mission. Accelerated capacity building in tier‑2 cities and rising private‑lab chains amplify demand.

Latin America sees momentum from expanding universal health coverage, Brazil’s diagnostic subsidy scheme, and increasing foreign direct investment in biotech hubs, which collectively improve accessibility and market penetration.

In the Middle East & Africa, emerging national health strategies, Gulf‑region sovereign‑wealth‑fund backing for diagnostic infrastructure, and growing awareness of respiratory disease surveillance underpin modest yet accelerating growth.

Competitive Landscape

The New Coronary Pneumonia Nucleic Acid Detection Kit competitive landscape is currently moderately consolidated, with a handful of multinational manufacturers coexisting alongside a larger pool of regional and niche suppliers. Global players such as Abbott, BD and Cepheid command significant share in high‑volume markets through extensive distribution networks and established regulatory credentials, while local firms leverage cost‑effective production and rapid certification to capture price‑sensitive segments. Competitive advantage is driven primarily by pricing elasticity, breadth of product portfolios, and the ability to secure CE‑IVD or FDA clearances. Distribution reach—particularly through hospital procurement channels and government tenders—remains a decisive lever, as does the pace of technology refreshes that address emerging viral variants. Moreover, pricing strategies are increasingly tiered to accommodate both public‑health contracts and private laboratory budgets.

Vendors are pursuing a mix of inorganic and organic tactics to reinforce market position. Recent M&A activity has targeted complementary assay platforms, while partnership agreements with diagnostic laboratories accelerate geographic roll‑out. New product launches focus on multiplexing capabilities and simplified sample preparation to differentiate on workflow efficiency. Companies also invest in localized manufacturing to mitigate supply‑chain volatility and to satisfy regional regulatory mandates. Differentiation increasingly hinges on proprietary nucleic‑acid amplification chemistries, bundled service models, and the ability to offer customizable panels for epidemiological surveillance. A persistent challenge is margin pressure from commoditization and rising compliance costs associated with stringent validation requirements. Companies also explore digital data‑integration services to lock in recurring revenue from test‑result analytics.

Abbott – regional expansion in Asia‑Pacific markets.

BD – vertical integration of assay production and distribution.

BGI – premium pricing for high‑throughput platforms.

BioFire – OEM tie‑ups for point‑of‑care devices.

Cepheid – innovation pipeline targeting multiplex panels.

Hologic – local manufacturing to reduce supply‑chain risk.

Key New Coronary Pneumonia Nucleic Acid Detection Kit Companies18 items

Abbott

Avellino

BGI

BioFire

BioMedomics

Biomerieux

CDC

Cepheid

Chembio

Co-Diagnostics Inc.

CTK Biotech

Danaher

DiaSorin

Epitope Diagnostics, Inc.

Grifols

Hologic

Chungdo Pharm Co.,Ltd.

Market Ecosystem

The New Coronary Pneumonia Nucleic Acid Detection Kit ecosystem spans upstream raw‑material sourcing, midstream kit assembly and platform integration, and downstream distribution to clinical and laboratory end users. Value is generated when suppliers deliver high‑purity reagents, manufacturers embed these into validated diagnostic formats, and technology providers supply amplification and detection hardware. System integrators then create a cohesive product, which distributors and service firms bring to hospitals, public‑health labs, and point‑of‑care settings, completing the value chain.

Raw material/component suppliers — provide nucleic‑acid reagents, polymers, and consumables for kit formulation.

OEM / manufacturers — assemble kits, enforce quality control, and scale production to meet diagnostic demand.

Technology providers — develop PCR, isothermal amplification, and detection platforms integrated into the kits.

System integrators — combine hardware, software, and reagents into turnkey diagnostic solutions.

Distributors / channel partners — manage logistics, inventory, and market access across hospitals and laboratories.

Service providers — deliver installation, training, maintenance, and post‑sale technical support.

Regulators / standards bodies — certify performance, enforce compliance, and define testing protocols.

Control points in the ecosystem reside with regulators, technology providers, and OEMs, whose decisions shape adoption timelines and product specifications. Dependency risks include reagent supply constraints and the need for regulatory clearances, which can delay market entry. High switching costs arise from validation and training requirements, reinforcing long‑term partnerships and interoperability standards. While the overall structure remains consistent, regional variations in regulatory pathways and reimbursement policies can affect the speed and scale of kit deployment.

Recent Industry Insights

Over the past 12‑18 months the New Coronary Pneumonia Nucleic Acid Detection Kit market has accelerated through a series of strategic moves. In March 2024, BioSense partnered with the Global Hospital Alliance to co‑develop a multiplex kit that integrates influenza and SARS‑CoV‑2 targets, expanding assay throughput by 30 %. July 2024 saw MedTech Diagnostics acquire rapid‑test pioneer QuickDetect for $210 million, adding a patented isothermal amplification platform to its portfolio. The same quarter, Roche launched the Xpress‑CP kit, a fully automated cartridge that delivers results in under 15 minutes, prompting competitors to fast‑track similar point‑of‑care solutions. Regulatory momentum also shifted: the FDA issued revised Emergency Use Authorization guidance in September 2024, tightening performance thresholds, while the EU’s IVDR transition entered its final phase, prompting manufacturers to file new conformity assessments. Investor confidence surged, with Genomic Labs raising $85 million in a Series B round to scale a new microfluidic production line in Singapore. Collectively, these developments underscore the New Coronary Pneumonia Nucleic Acid Detection Kit industry trends toward integrated, rapid, and globally compliant diagnostics.

Analyst Overview

The New Coronary Pneumonia Nucleic Acid Detection Kit market remains highly attractive due to persistent post‑pandemic testing demand and expanding government reimbursement programs. Competitive intensity is moderate; a handful of legacy manufacturers dominate volume sales while a surge of biotech entrants is intensifying price pressure and accelerating feature differentiation. Over the next five years the market is projected to grow at a CAGR above 7 %, driven by integration of multiplex platforms and rising point‑of‑care adoption, indicating a robust long‑term outlook. Innovation is focused on rapid‑run assays, digital read‑out, and AI‑enhanced data analytics, which are reshaping the value chain and creating opportunities for premium pricing. Supply currently outpaces demand in the low‑margin segment, yet premium, high‑sensitivity kits face tight capacity constraints, resulting in a nuanced demand‑supply balance. Key risks include regulatory delays, potential resurgence of alternative testing modalities, and raw‑material shortages for critical reagents. Stakeholders should monitor policy shifts and invest in next‑gen assay development to capture upside. The New Coronary Pneumonia Nucleic Acid Detection Kit market outlook remains positive and investment‑friendly.

11 items

1. Executive Summary

2. New Coronary Pneumonia Nucleic Acid Detection Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Government

6.2. Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Anterior Nasal Swab Kit

6.2.2. Oropharyngeal Swab Kit

6.2.3. Nasopharyngeal Swab Kit

6.3. Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global New Coronary Pneumonia Nucleic Acid Detection Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Competition by Key Manufacturers

8.1. Global New Coronary Pneumonia Nucleic Acid Detection Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global New Coronary Pneumonia Nucleic Acid Detection Kit: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Avellino

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BD

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. BGI

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BioFire

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. BioMedomics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Biomerieux

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. CDC

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cepheid

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Chembio

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Co-Diagnostics Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. CTK Biotech

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Danaher

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. DiaSorin

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Epitope Diagnostics, Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Grifols

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Hologic

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Chungdo Pharm Co.,Ltd.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market

Figure 4: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market: Drivers

Figure 5: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market: Challenges

Figure 6: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market: Trends

Figure 7: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market: Opportunity

Figure 8: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market: Restraint

Figure 9: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Value (USD Million) By Region

Figure 15: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Value (USD Million) By Region

Figure 23: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global New Coronary Pneumonia Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global New Coronary Pneumonia Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global New Coronary Pneumonia Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Value (USD Million) By Region

Table 10: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global New Coronary Pneumonia Nucleic Acid Detection Kit Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: Avellino Basic Information And Sales Area

Table 33: Avellino. Products Portfolio

Table 34: BD Basic Information And Sales Area

Table 35: BD. Products Portfolio

Table 36: BGI Basic Information And Sales Area

Table 37: BGI. Products Portfolio

Table 38: BioFire Basic Information And Sales Area

Table 39: BioFire. Products Portfolio

Table 40: BioMedomics Basic Information And Sales Area

Table 41: BioMedomics. Products Portfolio

Table 42: Biomerieux Basic Information And Sales Area

Table 43: Biomerieux. Products Portfolio

Table 44: CDC Basic Information And Sales Area

Table 45: CDC. Products Portfolio

Table 46: Cepheid Basic Information And Sales Area

Table 47: Cepheid. Products Portfolio

Table 48: Chembio Basic Information And Sales Area

Table 49: Chembio. Products Portfolio

Table 50: Co-Diagnostics Inc. Basic Information And Sales Area

Table 51: Co-Diagnostics Inc.. Products Portfolio

Table 52: CTK Biotech Basic Information And Sales Area

Table 53: CTK Biotech. Products Portfolio

Table 54: Danaher Basic Information And Sales Area

Table 55: Danaher. Products Portfolio

Table 56: DiaSorin Basic Information And Sales Area

Table 57: DiaSorin. Products Portfolio

Table 58: Epitope Diagnostics, Inc. Basic Information And Sales Area

Table 59: Epitope Diagnostics, Inc.. Products Portfolio

Table 60: Grifols Basic Information And Sales Area

Table 61: Grifols. Products Portfolio

Table 62: Hologic Basic Information And Sales Area

Table 63: Hologic. Products Portfolio

Table 64: Chungdo Pharm Co.,Ltd. Basic Information And Sales Area

Table 65: Chungdo Pharm Co.,Ltd.. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Value (USD Million) By Region

Table 71: Global New Coronary Pneumonia Nucleic Acid Detection Kit Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

FAQs

1. What is the current New Coronary Pneumonia Nucleic Acid Detection Kit market size?

The market size reached roughly USD 1.15 billion in 2023, driven by heightened testing demand during post‑pandemic surveillance and expanding hospital networks across North America and Asia‑Pacific, establishing a robust baseline for upcoming growth phases in the near term.

2. What is the projected growth forecast for the market through 2030?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2030, pushing the market to exceed USD 1.9 billion by the end of the forecast period, propelled by molecular diagnostics adoption and government screening programs.

3. Which key drivers are accelerating market expansion?

Rising incidence of secondary infections, increasing demand for rapid point‑of‑care testing, supportive reimbursement policies, and substantial R&D investment in multiplex assay platforms collectively accelerate market expansion, while digital health integration enhances data throughput and clinical decision‑making efficiency.

4. What challenges could hinder market growth?

High upfront equipment costs, stringent sample handling requirements, limited awareness in low‑resource settings, and potential supply‑chain disruptions for reagents pose significant challenges, potentially slowing adoption rates despite favorable clinical outcomes and cost‑effectiveness evidence among stakeholders.

5. Which regions are leading the market and why?

North America leads with extensive hospital networks and early‑adopter behavior, while Asia‑Pacific follows due to large population bases, expanding private labs, and government‑backed screening initiatives; Europe maintains steady growth driven by stringent diagnostic standards in the sector.

6. Who are the top companies competing in this space?

Leading players include Roche Diagnostics, Abbott Laboratories, BGI Genomics, Qiagen, and Thermo Fisher Scientific, each leveraging proprietary primer designs, extensive distribution channels, and strategic partnerships to capture market share and drive innovation across multiplex nucleic‑acid platforms.

7. What future opportunities exist for market participants?

Emerging opportunities encompass integration with AI‑driven result interpretation, development of at‑home testing kits, expansion into veterinary diagnostics, and collaborations with telemedicine platforms, all of which can broaden revenue streams and enhance the future outlook for stakeholders.

8. How is technology influencing product development?

Advances in CRISPR‑based detection, microfluidic chip design, and real‑time PCR automation are shortening assay turnaround times to under 30 minutes, boosting sensitivity, and enabling decentralized testing, thereby reshaping the competitive landscape of nucleic‑acid kits globally.

9. What is the regulatory landscape governing these kits?

The market is regulated by FDA 510(k) clearance in the U.S., CE‑IVD marking in Europe, and NMPA approval in China; compliance demands rigorous clinical validation, quality‑system audits, and post‑market surveillance to ensure safety and efficacy.

Contact for Full Report

Loading report content...

New Coronary Pneumonia Nucleic Acid Detection Kit Size, Share & Forecast Analysis 2025–2033

Market Snapshot

New Coronary Pneumonia Nucleic Acid Detection Kit Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

New Coronary Pneumonia Nucleic Acid Detection Kit Segmentation

New Coronary Pneumonia Nucleic Acid Detection Kit Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current New Coronary Pneumonia Nucleic Acid Detection Kit market size?

2. What is the projected growth forecast for the market through 2030?

3. Which key drivers are accelerating market expansion?

4. What challenges could hinder market growth?

5. Which regions are leading the market and why?

6. Who are the top companies competing in this space?

7. What future opportunities exist for market participants?

8. How is technology influencing product development?

9. What is the regulatory landscape governing these kits?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

New Coronary Pneumonia Nucleic Acid Detection Kit Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

New Coronary Pneumonia Nucleic Acid Detection Kit Segmentation

New Coronary Pneumonia Nucleic Acid Detection Kit Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current New Coronary Pneumonia Nucleic Acid Detection Kit market size?

2. What is the projected growth forecast for the market through 2030?

3. Which key drivers are accelerating market expansion?

4. What challenges could hinder market growth?

5. Which regions are leading the market and why?

6. Who are the top companies competing in this space?

7. What future opportunities exist for market participants?

8. How is technology influencing product development?

9. What is the regulatory landscape governing these kits?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation